跳转至内容
Merck
CN

420132

JAK2 Inhibitor II

The JAK2 Inhibitor II, also referenced under CAS 1837-91-8, controls the biological activity of JAK2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

JAK2 Inhibitor II, 1,2,3,4,5,6-Hexabromocyclohexane

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C6H6Br6
化学文摘社编号:
1837-91-8
分子量:
557.54
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00059127

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

BrC1C(C(C(C(C1Br)Br)Br)Br)Br

InChI

1S/C6H6Br6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H

InChI key

QFQZKISCBJKVHI-UHFFFAOYSA-N

assay

≥97% (GC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

off-white

solubility

DMSO: 5 mg/mL

shipped in

ambient

Quality Level

100

相关类别

General description

A cell-permeable hexabromocyclohexane compound that interacts with a solvent-accessible pocket near the activation loop of JAK2 and acts as a specific, reversible, and direct inhibitor of JAK2 autophosphorylation (maximal inhibition at 50 µM in BSC-40 cells overexpressing JAK2). Reduces growth hormone-mediated JAK2 activation in γ2A cells that stably express growth hormone receptor and JAK2. Does not block EGFR autophosphorylation in murine fibroblasts.
A cell-permeable, specific, reversible, and direct inhibitor of JAK2 autophosphorylation (maximal inhibition at 50 µM in BSC-40 cells overexpressing JAK2 that interacts with a solvent-accessible pocket near the activation loop of JAK2. Reduces growth hormone-mediated JAK2 activation in γ2A cells that stably express growth hormone receptor and JAK2. Does not block EGFR autophosphorylation in murine fibroblasts.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
JAK2 autophosphorylation
Product does not compete with ATP.
Reversible: yes

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Sandberg, E.M., et al. 2005. J. Med. Chem.48, 2526.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Gerlinde Wernig et al.
Proceedings of the National Academy of Sciences of the United States of America, 114(18), 4757-4762 (2017-04-21)
Fibrotic diseases are not well-understood. They represent a number of different diseases that are characterized by the development of severe organ fibrosis without any obvious cause, such as the devastating diseases idiopathic pulmonary fibrosis (IPF) and scleroderma. These diseases have

相关内容

JAK/STAT Signaling Research Focus

The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway plays an important role in cell proliferation, cell differentiation, cell migration, and cell death. It is the principal signaling mechanism for a variety of cytokines and growth factors. Constitutive activation or dysregulation of JAK/STAT signaling can result in inflammatory disease, erythrocytosis, gigantism, and leukemia.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持